Activates GLP-1, GIP and glucagon receptors.
MAD participants meanBMI 31.4; randomized otherwise healthy cohort
Study contextChina phase 2 planned; non-China phase 1 planned 2026 with 2027 data.
Status & indications16% reported weight loss · 5.4% loss with placebo · 12 weeks
HRS-4729 phase 1 MAD · Phase 1 · sponsor · 12 mg once weekly · Other / incompletely specified
Evidence & limitationsMost reported adverse events were mild or moderate gastrointestinal events.
Safety contextA next milestone is not summarized for this therapy.
Milestone detailsStudy results apply to their own population, dose and analysis. They do not establish a ranking between therapies.
Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.
16% reported weight loss · 5.4% loss with placebo · 12 weeks
12 mg once weekly
MAD participants meanBMI 31.4; randomized otherwise healthy cohort
Not specified in public report China phase 2 planned; non-China phase 1 planned 2026 with 2027 data.
Most reported adverse events were mild or moderate gastrointestinal events.
Limitations: Small first-in-human cohort; sponsor says 'up to'; estimand unspecified. Phase 1 should be visibly distinguished.
Status in this atlas: China phase 2 planned; non-China phase 1 planned 2026 with 2027 data.
Activates GLP-1, GIP and glucagon receptors.
No approved trade name verified as of September 13, 2026; the compound name and development codes are not trade names.
Hengrui Pharma · Originator and Greater-China developer.; Kailera Therapeutics · Exclusive development and commercialization licensee outside China, Hong Kong, Macau and Taiwan.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
Activates GLP-1, GIP and glucagon receptors.
Shown: Peptide drug
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.
HRS-4729 (KAI-4729)HRS-4729 (KAI-4729) · compound history across indications
Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.
Hengrui licensed the metabolic portfolio to Kailera for worldwide development and commercialization outside Greater China.
SourceKailera reported the Chinese 12-week multiple-dose study; Hengrui planned phase 2 development in obesity and MASH.
SourceSelected sources checked Sep 13, 2026. This is not an exhaustive history.